Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Traynor

Showing results (131-140 of 161) with videos related to

Pageof 17
Sort By:
Cancer Chemotherapy and Pharmacology|January 22, 2016
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumorsJustine Yang Bruce, Patricia M LoRusso, Priscila H Goncalves, et al.
Academic Medicine :, Journal of the Association of American Medical Colleges|July 28, 2025
Building Pathways to Clinical Research Careers: Partnerships With Academic Programs to Provide Students With Experiential Learning Opportunities in Clinical ResearchSharleen M Traynor, Tracie D Locklear, Stephanie A Freel, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cellsLauren Sarko, David Givand, Claire Shepley, et al.
Investigational New Drugs|December 25, 2012
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network studyNoelle K LoConte, Kyle D Holen, William R Schelman, et al.
Pediatric Neurology|January 7, 2022
Sepsis-Related Brain MRI Abnormalities Are Associated With Mortality and Poor Neurological Outcome in Pediatric SepsisAndrew E Becker, Sara R Teixeira, Nicholas A Lunig, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2015
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusionMatthew J Nyflot, Tim J Kruser, Anne M Traynor, et al.
Clinical Breast Cancer|December 18, 2013
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network studyMark E Burkard, Kari B Wisinski, Uchenna O Njiaju, et al.
The Oncologist|October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung CancerAlberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2013
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancerAnne M Traynor, Tracey L Weigel, Kurt R Oettel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trialGeorge R Simon, Claire F Verschraegen, Pasi A Jänne, et al.
Pageof 17

Showing results (131-140 of 161) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|January 22, 2016
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumorsJustine Yang Bruce, Patricia M LoRusso, Priscila H Goncalves, et al.
Academic Medicine :, Journal of the Association of American Medical Colleges|July 28, 2025
Building Pathways to Clinical Research Careers: Partnerships With Academic Programs to Provide Students With Experiential Learning Opportunities in Clinical ResearchSharleen M Traynor, Tracie D Locklear, Stephanie A Freel, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cellsLauren Sarko, David Givand, Claire Shepley, et al.
Investigational New Drugs|December 25, 2012
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network studyNoelle K LoConte, Kyle D Holen, William R Schelman, et al.
Pediatric Neurology|January 7, 2022
Sepsis-Related Brain MRI Abnormalities Are Associated With Mortality and Poor Neurological Outcome in Pediatric SepsisAndrew E Becker, Sara R Teixeira, Nicholas A Lunig, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2015
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusionMatthew J Nyflot, Tim J Kruser, Anne M Traynor, et al.
Clinical Breast Cancer|December 18, 2013
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network studyMark E Burkard, Kari B Wisinski, Uchenna O Njiaju, et al.
The Oncologist|October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung CancerAlberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2013
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancerAnne M Traynor, Tracey L Weigel, Kurt R Oettel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trialGeorge R Simon, Claire F Verschraegen, Pasi A Jänne, et al.
Pageof 17